

# Use of external quality assessment schemes in the assessment of the performance of in vitro diagnostic examination procedures

The European Standard EN 14136:2004 has the status of a British Standard

ICS 11.100

## National foreword

This British Standard is the official English language version of EN 14136:2004.

The UK participation in its preparation was entrusted to Technical Committee CH/212, IVDs, which has the responsibility to:

- aid enquirers to understand the text;
- present to the responsible international/European committee any enquiries on the interpretation, or proposals for change, and keep the UK interests informed;
- monitor related international and European developments and promulgate them in the UK.

A list of organizations represented on this committee can be obtained on request to its secretary.

### Cross-references

The British Standards which implement international or European publications referred to in this document may be found in the *BSI Catalogue* under the section entitled “International Standards Correspondence Index”, or by using the “Search” facility of the *BSI Electronic Catalogue* or of British Standards Online.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

**Compliance with a British Standard does not of itself confer immunity from legal obligations.**

This British Standard was published under the authority of the Standards Policy and Strategy Committee on 26 May 2004

### Summary of pages

This document comprises a front cover, an inside front cover, the EN title page, pages 2 to 11 and a back cover.

The BSI copyright notice displayed in this document indicates when the document was last issued.

### Amendments issued since publication

Amd. No.	Date	Comments

© BSI 26 May 2004

ISBN 0 580 43819 8

---

ICS 11.100

English version

## Use of external quality assessment schemes in the assessment of the performance of in vitro diagnostic examination procedures

Utilisation des programmes d'évaluation externe de la  
qualité dans l'évaluation de la performance des procédures  
de diagnostic in vitro

Verwendung externer Qualitätssicherungsprogramme bei  
der Bewertung der Durchführung von  
Untersuchungsverfahren in der In-vitro-Diagnostik

This European Standard was approved by CEN on 2 March 2004.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the Central Secretariat or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the Central Secretariat has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION  
COMITÉ EUROPÉEN DE NORMALISATION  
EUROPÄISCHES KOMITEE FÜR NORMUNG

Management Centre: rue de Stassart, 36 B-1050 Brussels

## **Foreword**

This document (EN 14136:2004) has been prepared by Technical Committee CEN/TC 140 "In vitro diagnostic medical devices", the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by November 2004, and conflicting national standards shall be withdrawn at the latest by November 2004.

This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directive(s).

For relationship with EU Directive(s), see informative Annex ZA, which is an integral part of this document.

This document includes a Bibliography.

According to the CEN/CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland and United Kingdom.

## Introduction

External quality assessment schemes (EQAS) are an essential feature of mechanisms designed to maintain and improve the analytical quality and medical appropriateness of clinical laboratory data. EQAS are most highly developed in fields in which mostly quantitative, numerical data are generated; notably in clinical chemistry, haematology, immunology, etc. However, EQAS can also be extended to qualitative or more subjective investigations such as in microbiology and parasitology, as well as in histo- or cytopathology.

Participation and acceptable performance in EQAS serve a valuable function in raising standards in laboratory medicine and in educating providers and users about the potential benefits and limitations of laboratory examinations. Objective data provided by EQAS are an essential component of efforts to relate the current state of the art of laboratory performance to medical needs.

EQAS are already essential parts of laboratory accreditation systems, whether mandatory or not, in member states of the European Union. Good clinical laboratory practice includes both external quality assessment and internal quality control as complementary components of quality assurance.

In addition to the major objectives of EQAS (see ISO/IEC Guide 43-1), data from EQAS can also provide a valuable resource in enabling comparisons to be made between alternative new or established analytical procedures (including in vitro diagnostic medical devices hereafter called IVD MDs), or in demonstrating the transferability of procedures between laboratories, or in disclosing difficulties or deficiencies in their operation that can only become apparent during long-term and widespread use. An EQAS in which the survey samples have reference procedure values can provide evidence of the trueness of results obtained by using different procedures; an EQAS in which the same survey samples are circulated repeatedly and frequently can demonstrate reproducibility and, e. g., the possible effects of changes in the properties of an IVD MD.

The major objectives of individual EQAS differ, ranging from those that are directed principally towards ensuring compliance with specific proficiency targets, to those that are aimed at a general survey and improvement of particular services: e. g., in developing a network of participation, or in establishing criteria for evaluating performance of more subjective investigations. Thus, details of schemes such as organisation (e.g., by regulatory authorities, professional societies or industrial concerns), nature and frequency of sample distribution, and assessment of results, differ from one scheme to another.

Because of the differing functions and objectives of EQAS, it is neither possible nor desirable to impose a single pattern of organisation on all such schemes, and this European Standard does not intend to do so. The general principles for the design and the operation of EQAS are outlined in ISO/IEC Guide 43-1 and include:

- use of appropriate survey samples;
- effective distribution to participants (e. g. laboratories and/or point-of-care testing sites);
- rapid processing of survey data ;
- return to participants of reports that are clearly interpreted with respect to stated criteria;
- mechanisms for follow-up of unsatisfactory performance (e.g. through advice services).

**In order to enable EQAS to provide data that are useful in monitoring the analytical performance of specific procedures (including IVD MDs), additional features are used. For example, EQAS should unequivocally identify individual procedures (devices) used in statistically significant numbers, and above all, they should be able to distinguish performance characteristics inherent in a particular procedure (device) from those attributable to its users.**

This European Standard specifies ways in which EQAS can meet these procedure (device)-related criteria. Thus, EQAS is able to contribute to the post-marketing monitoring of IVD MDs as mentioned in Directive 98/79/EC on in vitro diagnostic medical devices to the benefit of both their manufacturers and users.

## 1 Scope

This European Standard applies to external quality assessment schemes, hereafter called EQAS, that include in their functions the assessment and evaluation of the performance of specified in vitro diagnostic procedures (including in vitro diagnostic medical devices, hereafter called IVD MDs). It sets out the requirements that are necessary to enable EQAS to fulfil this function relating to:

- scheme design and organisation;
- identification of procedures (IVD MDs) used by the participant;
- classification and evaluation of data.

NOTE External quality assessment data generated according to these criteria will help manufacturers, users or competent authorities to monitor independently the post-marketing performance of IVD MDs.

This European Standard does not specify ways in which EQAS themselves are organised, nor how the individual or collective performance of clinical laboratories is evaluated.

## 2 Normative references

This European Standard incorporates by dated or undated reference, provisions from other publications. These normative references are cited at the appropriate places in the text, and the publications are listed hereafter. For dated references, subsequent amendments to or revisions of any of these publications apply to this European Standard only when incorporated in it by amendment or revision. For undated references the latest edition of the publication referred to applies (including amendments).

EN 375:2001, *Information supplied by the manufacturer with in vitro diagnostic reagents for professional use.*

EN 12286:1998, *In vitro diagnostic medical devices — Measurement of quantities in samples of biological origin — Presentation of reference measurement procedures.*

EN 45003:1995, *Calibration and testing laboratory accreditation system — General requirements for operation and recognition.*

EN ISO 15195, *Laboratory medicine - Requirements for reference measurement laboratories (ISO/FDIS 15195:2003).*

EN ISO 17511, *In vitro diagnostic medical devices - Measurement of quantities in biological samples - Metrological traceability of values assigned to calibrators and control materials (ISO 17511:2003).*

EN ISO 18153, *In vitro diagnostic medical devices - Measurement of quantities in biological samples - Metrological traceability of values for catalytic concentration of enzymes assigned to calibrators and control materials (ISO 18153:2003).*

ISO 3534-1:1993, *Statistics — Vocabulary and symbols — Part 1: Probability and general statistical terms.*

International Vocabulary of Basic and General Terms in Metrology (VIM), 2nd edition, Geneva: ISO, 1993

## 3 Terms and definitions

For the purposes of this European Standard, the terms and definitions given in EN 375:2001, EN 12286:1998, EN ISO 17511:2003, EN 45003:1995, ISO 3534-1:1993, the International Vocabulary of Basic and General Terms in Metrology (VIM) and the following apply.

**3.1****assigned value**

value attributed to a particular quantity and accepted, sometimes by convention, as having an uncertainty appropriate for a given purpose [ISO/IEC Guide 43-1:1997]

**3.2****external quality assessment****EQA**

determination of individual and collective laboratory performance, and performance characteristics of examination procedures by means of interlaboratory comparison

NOTE The primary objectives of EQA are educational, and can be supported by additional elements.

**3.3****nominal scale**

scale with a set of possible values, for a given kind-of-property, that are each designated by a word or symbol without any relation to magnitude

EXAMPLE Blood group (A, B, AB, 0)

NOTE The values can be listed in any arbitrary order according to practical considerations and convention.

**3.4****ordinal scale**

scale with an ordered set of possible values, for properties of a given kind-of-property, that are each designated by a word or symbol used for ranking according to magnitude, but where differences or ratios between values have no arithmetic meaning

EXAMPLES Wording such as "not detected", "weakly positive", "positive", "strongly positive" or figures such as 0, 1, 2, 3.

**3.5****target value**

accepted reference value

NOTE Examples of target values are assigned values, reference procedure values, and consensus values.

**3.6****reference measurement procedure**

thoroughly investigated measurement procedure shown to yield values having an uncertainty of measurement commensurate with its intended use, especially in assessing the trueness of other measurement procedures for the same quantity and in characterizing reference materials [EN 12286:1998, 3.7]

**3.7****reference procedure value**

value obtained by a reference measurement procedure

**3.8****survey sample**

sample sent to participants for selected examination, where the result is returned to the EQAS organisation for independent assessment of performance

**4 Design requirements for EQAS**

**4.1** The EQAS organisation shall formulate the objectives of its surveys at its start.

**4.2** The EQAS organisation shall provide survey samples composed in such a way that they simulate as closely as possible the relevant properties of the samples on which the examination procedures are intended to be used.

NOTE 1 For assigning target values to survey samples see EN ISO 17511.

## EN 14136:2004 (E)

NOTE 2 For some evaluations it can be appropriate to use a set of survey samples with different target values.

NOTE 3 The responsibility of the EQAS organisation for providing survey samples with appropriate properties is set out in ISO/IEC Guide 43-1.

NOTE 4 EQAS organisations should not select survey samples containing unphysiological additives which may disadvantage an individual IVD MD.

**4.3** The frequency of surveys shall be appropriate for the investigation, and preferably at least 6 times per year. In order to allow evaluation of recent IVD MD performance the survey data shall be available as soon as feasible after return of results.

**4.4** In order to assess the performance of a particular IVD MD, the design of the EQAS shall enable a device- or procedure-specific evaluation of results.

NOTE Examination can comprise a combination of IVD MDs, e.g. instrument, reagent and calibration material.

**4.5** For each IVD MD supplied by an individual manufacturer, frequency distributions, measures of central tendency (e.g. median) and measures of dispersion (e.g. standard deviation, quantiles) of the participants' results shall be reported when the number of participants is appropriate for statistical evaluation.

NOTE 1 When different IVD MDs, that are intended to examine the same quantity, claim metrological traceability of their calibration to the same reference measurement procedure the central tendencies of their distributions should converge towards the target value obtained by applying the reference measurement procedure to the same samples.

NOTE 2 The EQAS organisation should have, if appropriate, access to laboratories approved according to EN ISO 15195 which can assign reference procedure values with stated uncertainty and metrological traceability.

**4.6** The EQAS shall be designed such that the EQAS organisation shall be able to distinguish the performance of the individual participants from the performance of the procedure as it is done in general.

**4.7** The choice of the technique employed for assigning values to the survey samples shall be appropriate for the intended investigation.

NOTE 1 Examples of assigned values are:

- reference procedure value,
- value derived from known composition,
- procedure-dependent or -independent consensus value.

NOTE 2 It is preferable to use assigned values with defined uncertainties.

**4.8** When values are assigned by an internationally accepted reference measurement procedure the requirements of EN 12286, EN ISO 15195 and EN ISO 17511 shall be followed.

**4.9** The EQAS organisation shall document how assigned values have been determined.

## 5 Requirements for organisations conducting EQAS

**5.1** An EQAS shall be conducted by a competent organisation established in the field of medical laboratory examinations.

**5.2** The EQAS organisation shall have an independent medical and scientific advisory committee.

**5.3** The EQAS organisation shall be free from any commercial, financial or other conflicting interests - whether internal or external - which might influence its independent judgement or adversely affect the quality of work.

NOTE National authorities can state additional requirements for the qualification of the EQAS organisation.



**5.4** The EQAS shall be organised in such a way that all parties involved maintain confidence in its independent judgement at all times.

**5.5** The EQAS organisation shall establish and maintain a quality management system.

NOTE 1 ISO/IEC Guide 43-1 and ILAC–G13:2000 give examples for a quality management system.

NOTE 2 The organisation should be accredited by a national or European accreditation body and/or acknowledged by a national authority.

## 6 Assessment of analytical examination procedures

### 6.1 General

**6.1.1** The nature of the survey samples and the assigned values, where applicable, shall be appropriate to the objectives of the particular EQA round and to the IVD MDs assessed.

**6.1.2** Results shall be reported for each individual in vitro diagnostic examination procedure and assessed according to the claims made for the procedure.

**6.1.3** If a value assigned to a survey sample is claimed to be traceable to a specified metrological level the requirements of EN ISO 17511 and EN ISO 18153 shall apply.

**6.1.4** Data from an EQA survey shall be assessed by applying statistical techniques, appropriate for the type of property examined. The statistical technique(s), including outlier identification procedures, shall be described by the EQA organisation and made available to the participants of the scheme.

NOTE 1 See also ISO/IEC Guide 43-1.

NOTE 2 Performance assessment which is based on data from more than one sample as well as more than one user should be more reliable, and is recommended. The number of samples and/or frequency of surveys will depend on the EQAS design.

NOTE 3 See also ISO/DIS 13528.

**6.1.5** The results obtained by EQAS shall be interpreted according to criteria for acceptable performance, and in relation to the claims of the manufacturer for that IVD MD.

NOTE 1 Criteria for acceptable performance should reflect the medical use (e.g. based on biological variation or other means) and the "state-of-the-art" of the quality of the IVD MDs. In some countries national legislation, rules or guidelines provide such criteria. EQA organisers, at a national or regional level, should seek consensus on the criteria applied, taking into account 6.1.4.

NOTE 2 For quantities which are not traceable to SI units, fitness for purpose, i.e. medical requirements, should be emphasised, while awaiting internationally-agreed consensus-based reference measurement systems. A 95 % centile performance criterion applied on the data of *all* laboratories reporting on the same quantity does not take into account the understanding that each procedure may generate a unique answer. In these cases, a single assigned value for *all* IVD MDs purporting to measure the same substance, is not appropriate. Therefore, a survey report should give results of each procedure separately for the group of laboratories employing that procedure. An unvalidated all-laboratory mean should be avoided for assessment of performance of products measuring these substances. When international consensus has been reached on a reference measurement system for such a substance an assigned value or a reference procedure value can be established.

**6.1.6** The EQA organiser shall gather sufficient information linked to the results, for reliable assessment of the results (e.g. kit identification, calibrator, measuring equipment).

**6.1.7** Conclusions on the performance of a particular IVD MD shall only be made if obtained when using the operating procedures recommended by the manufacturer (e.g. reagent-calibrator-instrument setting combinations).

NOTE 1 The user should be requested to declare whether the IVD MD was used in accordance with the instructions for use.

NOTE 2 Results from participants who are known or identified not to use the IVD MD in accordance with the manufacturer's instructions should not be included in the performance monitoring of that product.

## **6.2 Assessment procedure for quantitative results on ratio or difference scales**

**6.2.1** Assessment of IVD MD results shall be based not only on individual and average deviation of results from assigned values but also on the variability (spread) of results between users.

**6.2.2** Distributions of results shall be initially assessed to reveal the presence of bias and/or variability problems.

NOTE 1 Each of the following performance characteristics can reveal deficiencies in a procedure or IVD MD:

Bias (see also 6.1.5) can derive from e.g.:

- incorrect execution of the measurement procedure;
- incorrect calibration;
- different specificities (between procedures);
- susceptibility to interference;
- lack of commutability of survey sample.

Variability can derive from e. g. :

- incorrect execution of the measurement procedure;
- lot-related differences;
- susceptibility to operator or instrument influences;
- susceptibility to deterioration in shipment or in use.

NOTE 2 Changes in performance can indicate a problem which is developing. For example, an increasing bias with increasing variability could result from new lots of an IVD MD with performance that differs unexpectedly from previous lots.

## **6.3 Assessment of qualitative results on nominal scales or quantitative results on ordinal scales**

**6.3.1** The results of in vitro diagnostic examinations leading to such analytical results and identifications in EQAS shall be reported

- by a nominal scale

NOTE 1 In vitro diagnostic examinations which generate such results in EQAS are for example the examination for:

- ABO and RhD blood groups, irregular antibodies;
- blood cell morphology;
- the presence or absence of microorganisms, viruses or infectious agents;
- the presence or absence of specific antibodies;
- the presence or absence of genes or of certain DNA sequences

or

- by an ordinal scale.

NOTE 2 In vitro diagnostic examinations which generate results expressed on ordinal scales are for example the measurement of arbitrary concentrations of protein, glucose or blood in urine.

**6.3.2** Performance assessment for IVD MDs for examinations using nominal or ordinal scales (e.g. organism identification or virus screening investigations) shall be based on appropriate principles.

NOTE Many EQAS organisations use for these examinations a numerical scoring system which can be used for assessment of performance of procedures as well as for individual laboratories. Diagnostic reliability and variability between laboratories are equivalent to bias and variability for quantitative analyses but require other statistical techniques.

## **7 Using results to identify possible deficiencies**

**7.1** Where EQAS data indicate an apparent problem, the situation shall be investigated further.

NOTE In this case the EQAS data should be compared with the supplier's claimed performance. Performance can be re-evaluated relative to a method of higher metrological order and on appropriate clinical samples.

**7.2** In case of perceived malfunction of an IVD MD, the EQAS organisation shall inform the manufacturer or the authorized representative in the first instance.

NOTE The EQAS organisation can also inform the competent authorities.

## **8 Archiving documents**

All documents relating to the setting of an assigned value on survey samples shall be filed and kept for an appropriate period in accordance with national regulations.

## **9 Confidentiality**

The policy of the EQAS shall maintain confidentiality of the identity of individual participants unless the participants decide to waive anonymity.

**Annex ZA**  
(informative)

**Clauses of this European Standard addressing essential requirements or other provisions of EU Directives**

This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association and supports essential requirements of Directive 98/79/EC.

Compliance with this standard provides one means of conforming with the specific essential requirements of the Directive concerned and associated EFTA regulations.

**WARNING** Other requirements and other EU Directives may be applicable to the products falling within the scope of this standard.

## Bibliography

- ISO 1000, *SI units and recommendations for the use of their multiples and of certain other units*.
- ISO/DIS 13528, *Statistical methods for use in proficiency testing by interlaboratory comparisons*
- EN ISO 15189, *Medical laboratories – Particular requirements for quality and competence (ISO/DIS 15189.2:2003)*.
- EN ISO/IEC 17025, *General requirements for the competence of calibration and testing laboratories (ISO/IEC 17025:1999)*.
- ISO/IEC Guide 43-1:1997, *Proficiency testing by interlaboratory comparisons — Part 1: Development and operation of proficiency testing schemes*.
- ISO/IEC Guide 43-2, *Proficiency testing by interlaboratory comparisons — Part 2: Selection and use of proficiency testing schemes by laboratory accreditation bodies*.
- Guide to the Expression of Uncertainty in Measurement, 1st edition, Geneva: ISO, 1993.
- ISO/Remco N 231: *Harmonised Proficiency Testing Protocol (1991)*.
- IUPAC: *The international harmonised protocol for the proficiency testing of analytical laboratories. ISO/Remco N 263 (1992)*.
- Bullock D. G. , Libeer J. C., Zender R.: *Minimal requirements for external quality assessment schemes for clinical laboratories in Europe; EQAnews, 1994; 5 (No 2):11*.
- Dybkaer R.: *Vocabulary for use in measurement procedures and description of reference materials in laboratory medicine. Eur J Clin Chem Clin Biochem 1997; 35:141-173*.
- Hill P., Uldall A., Wilding P.: *Fundamentals for external quality assessment. IFCC Guidelines (1996)*.
- Libeer J. C., Baadenhuijsen H., Fraser C. G., Hyltoft Petersen P., Ricos C., Stöckl D., Thienpont L.: *Characterisation and classification of external quality assessment schemes according to objectives such as evaluation of method and participant bias and standard deviation. Eur J Clin Chem Biochem 1996; 34:665-678*.
- Petersen P.H., Fraser C. G., Kallner A., Kenny D. (editors): *Strategies to Set Global Analytical Specifications in Laboratory Medicine; Scan J Clin Lab Invest, 1999; 59: 475-585*
- ILAC-G13:2000, *Guidelines for the Requirements for the Competence of Providers of Proficiency Testing Schemes (obtainable via [www.ilac.org](http://www.ilac.org))*
- International Council for Standardization in Haematology (ICSH): *Guidelines for organization and management of external quality assessment using proficiency testing, International Journal of Haematology, 1998; 68:45–52*.
- Uldall A. (editor): *Compendium on Advanced External Quality Assurance in Clinical Biochemistry, EQAnews 2000; 11 (No 1):1–150*.
- WHO, *Requirements and guidance for external quality assessment schemes for health laboratories WHO/DIL/LAB/99.2. World Health Organization, Geneva (1999)*
- EURACHEM/CITAC Guide, *Quantifying Uncertainty in Analytical Measurement, Second edition, 2000, ([www.eurachem.bam.de](http://www.eurachem.bam.de))*

---

---

## BSI — British Standards Institution

BSI is the independent national body responsible for preparing British Standards. It presents the UK view on standards in Europe and at the international level. It is incorporated by Royal Charter.

### Revisions

British Standards are updated by amendment or revision. Users of British Standards should make sure that they possess the latest amendments or editions.

It is the constant aim of BSI to improve the quality of our products and services. We would be grateful if anyone finding an inaccuracy or ambiguity while using this British Standard would inform the Secretary of the technical committee responsible, the identity of which can be found on the inside front cover.  
Tel: +44 (0)20 8996 9000. Fax: +44 (0)20 8996 7400.

BSI offers members an individual updating service called PLUS which ensures that subscribers automatically receive the latest editions of standards.

### Buying standards

Orders for all BSI, international and foreign standards publications should be addressed to Customer Services. Tel: +44 (0)20 8996 9001.  
Fax: +44 (0)20 8996 7001. Email: [orders@bsi-global.com](mailto:orders@bsi-global.com). Standards are also available from the BSI website at <http://www.bsi-global.com>.

In response to orders for international standards, it is BSI policy to supply the BSI implementation of those that have been published as British Standards, unless otherwise requested.

### Information on standards

BSI provides a wide range of information on national, European and international standards through its Library and its Technical Help to Exporters Service. Various BSI electronic information services are also available which give details on all its products and services. Contact the Information Centre.  
Tel: +44 (0)20 8996 7111. Fax: +44 (0)20 8996 7048. Email: [info@bsi-global.com](mailto:info@bsi-global.com).

Subscribing members of BSI are kept up to date with standards developments and receive substantial discounts on the purchase price of standards. For details of these and other benefits contact Membership Administration.  
Tel: +44 (0)20 8996 7002. Fax: +44 (0)20 8996 7001.  
Email: [membership@bsi-global.com](mailto:membership@bsi-global.com).

Information regarding online access to British Standards via British Standards Online can be found at <http://www.bsi-global.com/bsonline>.

Further information about BSI is available on the BSI website at <http://www.bsi-global.com>.

### Copyright

Copyright subsists in all BSI publications. BSI also holds the copyright, in the UK, of the publications of the international standardization bodies. Except as permitted under the Copyright, Designs and Patents Act 1988 no extract may be reproduced, stored in a retrieval system or transmitted in any form or by any means – electronic, photocopying, recording or otherwise – without prior written permission from BSI.

This does not preclude the free use, in the course of implementing the standard, of necessary details such as symbols, and size, type or grade designations. If these details are to be used for any other purpose than implementation then the prior written permission of BSI must be obtained.

Details and advice can be obtained from the Copyright & Licensing Manager.  
Tel: +44 (0)20 8996 7070. Fax: +44 (0)20 8996 7553.  
Email: [copyright@bsi-global.com](mailto:copyright@bsi-global.com).